Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | ELANE | P08246 | 5/20 | 0.40 |
| ▸ | IL1RN | P18510 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367398 | 1.00 | CTSS (0.44) | CTSSCTSLPSMB8PSMB9PSMB5 | |
| SCHEMBL2367824 | 0.89 | CTSK (0.43) | CTSSCTSLPSMB8PSMB9PSMB5 | |
| Trifluoroacetic Acid SCHEMBL27766395 | 0.87 | CTSL (0.45) | CTSSCTSLPSMB8PSMB9PSMB5 | |
| SCHEMBL2367014 | 0.85 | QRFPR (0.40) | CTSSCTSLPSMB5CTSKIL1RN | |
| SCHEMBL2367341 | 0.85 | ACE (0.45) | CTSSCTSLCTSK | |
| SCHEMBL2367418 | 0.85 | CTSS (0.44) | CTSSCTSLCTSKIL1RNERAP2 | |
| SCHEMBL2367197 | 0.85 | CTSS (0.44) | CTSSCTSLCTSKIL1RNERAP2 | |
| SCHEMBL13724068 | 0.84 | CTSL (0.50) | CTSSCTSLPSMB8PSMB9PSMB5 | |
| SCHEMBL13723094 | 0.84 | CTSL (0.50) | CTSSCTSLPSMB8PSMB9PSMB5 | |
| SCHEMBL2367498 | 0.83 | CTSS (0.46) | CTSSCTSLCTSKIL1RNERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSS 660/4885CTSL 196/4885PSMB8 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.